BioCentury | May 30, 2011
Clinical News

Genasense oblimersen sodium injection: Additional Phase III data

...N.J. Product: Genasense oblimersen sodium injection Business: Cancer Molecular target: Bcl-2 mRNA Description: Antisense agent targeting Bcl-2 mRNA...
BioCentury | Nov 8, 2010
Finance

Wanted: Less Dilution

...The company received two awards totaling $488,958, including one for Genasense, an antisense agent targeting Bcl-2 mRNA...
BioCentury | Jul 5, 2010
Clinical News

Genasense oblimersen: Updated Phase II data

...Berkeley Heights, N.J. Product: Genasense oblimersen Business: Cancer Molecular target: Bcl-2 mRNA Description: Antisense agent targeting Bcl-2 mRNA...
BioCentury | Jan 4, 2010
Finance

Whole lotta nothin'

...Genasense oblimersen failed in a Phase III trial in advanced melanoma. The antisense agent targeting Bcl-2 mRNA...
BioCentury | Dec 7, 2009
Clinical News

Genasense oblimersen sodium injection): Preliminary Phase II data

...N.J. Product: Genasense oblimersen sodium injection) Business: Cancer Molecular target: Bcl-2 mRNA Description: Antisense agent targeting Bcl-2 mRNA...
BioCentury | Nov 23, 2009
Clinical News

Genasense oblimersen sodium injection: Additional Phase III data

...N.J. Product: Genasense oblimersen sodium injection Business: Cancer Molecular target: Bcl-2 mRNA Description: Antisense agent targeting Bcl-2 mRNA...
BioCentury | Nov 2, 2009
Clinical News

Genasense oblimersen sodium injection: Phase III data

...N.J. Product: Genasense oblimersen sodium injection Business: Cancer Molecular target: Bcl-2 mRNA Description: Antisense agent targeting Bcl-2 mRNA...
BioCentury | Aug 13, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Interferon induced with helicase C domain 1 (IFIH1; MDA5); phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1; NOXA) Studies in cell culture and in mice suggest that double-stranded...
BioCentury | Jun 1, 2009
Regulation

Accelerated approvals in CLL

...Humanized mAb against CD52 Oral purine nucleoside analog Human mAb against CD20 Antisense agent targeting Bcl-2 mRNA...
BioCentury | May 25, 2009
Clinical News

Genasense injection oblimersen sodium: Phase III ongoing

...N.J. Product: Genasense injection oblimersen sodium Business: Cancer Molecular target: Bcl-2 mRNA Description: Antisense agent targeting Bcl-2 mRNA...
Items per page:
1 - 10 of 145